Innovative Diagnostic Portfolio ZEUS Scientific offers a diverse range of high-performance diagnostic solutions with recent expansions into predictive cardiac biomarkers and Lyme disease testing, presenting sales opportunities across infectious, autoimmune, and cardiovascular disease markets.

Recent Product Launches The launch of the FDA-cleared Zeus Borrelia Modified Two-Tiered Testing algorithm and the dIFine 30 System indicates a focus on cutting-edge, efficient testing platforms that could appeal to labs seeking advanced diagnostic accuracy and automation.

Acquisition Growth Strategy Being acquired by Sebia in 2022 positions ZEUS Scientific within a global diagnostics ecosystem, enabling access to broader distribution channels and potential collaborations with Sebia’s extensive network in oncology and genetic testing sectors.

Market Expansion Potential With a revenue range of $10M to $25M and innovative, FDA-approved tests addressing infectious and autoimmune diseases, ZEUS Scientific is well-positioned to expand its market share by targeting laboratories and healthcare providers prioritizing early and accurate diagnostics.

Technology and Data Capabilities Utilizing advanced technology stacks including digital immunofluorescence, rapid testing, and proprietary biomarkers, ZEUS Scientific can leverage data-driven sales approaches emphasizing their innovative features and clinical effectiveness to attract research institutions and large healthcare systems.